Summary of the Conference Call for Yidu Technology Industry Overview - National policies and local government support are accelerating the commercialization of AI in healthcare, particularly in ICU settings, where AI-assisted diagnosis has been included in medical service pricing projects, promoting the development of medical AI [2][4] - There is a significant difference in the application of AI in drug development versus diagnostic services, with diagnostic services advancing more rapidly and already being applied in pre-diagnosis, diagnosis, and post-diagnosis stages, enhancing efficiency and accuracy [2][5] Company Insights - Yidu Technology's main business includes big data platforms and solutions (for hospitals and regulatory agencies), life sciences solutions (for pharmaceutical companies), and health management platforms (for public health insurance), having served numerous top hospitals and pharmaceutical clients [2][10] - The company has connected its DeepSeek technology to 420 hospitals, with over 50% being top-tier hospitals [6] - Yidu Technology has launched a hardware-software integrated AI platform, compatible with mainstream chips and open-source large models, which has been implemented in over 20 hospitals and is expected to boost revenue [3][16] Financial Performance and Projections - The company operates on a fiscal year ending March 31, with expectations to break even in fiscal year 2026 or 2027, driven primarily by the big data platform [3][17] - The gross margin remains stable at around 40%, with good expense control, but the company has not yet achieved profitability [17] - The big data platform and solutions are expected to be the main growth drivers, while life sciences solutions are projected to recover in fiscal years 2026 to 2027 [18] Key Business Metrics - The big data platform has covered 2,800 hospitals and accumulated over 800 specialized disease databases, serving more than 40 health commission agencies [11] - The life sciences solutions segment serves 71 pharmaceutical companies, with a retention rate exceeding 100% for top clients [12] - The health management platform has reached 24 million users, providing a solid customer base for future C-end business development [14] AI Technology Impact - The company has processed and analyzed data from over 1.1 billion patient visits and 5.5 billion authorized medical records, ranking first in specific scenarios such as medical knowledge Q&A and medical language understanding [15] - The integration of DeepSeek into its framework and partnerships with major companies like Huawei and ByteDance help maintain industry leadership and expand the product ecosystem [15] Valuation and Target Price - The initial coverage uses a price-to-sales (PS) valuation method, with a target price of HKD 77 per share, based on a PS ratio of 77.7, and a buy rating assigned [19]

Summary of Conference Call Notes Company Overview - The company discussed is Yidu Technology, a pioneering innovator in the AI healthcare industry with a focus on deepening its expertise over the past decade [1][2]. Key Points and Arguments Industry and Data - Yidu Technology has accumulated 5.5 billion high-quality medical records, covering over 1.1 billion patient visits, which is a significant asset in the Chinese healthcare landscape where data is not typically available post-discharge [1][20]. - The company has developed a comprehensive disease knowledge graph that encompasses all known diseases, supported by various specialized datasets and models [2][19]. Product and Application - The company offers a range of products, including a project management platform and an AI middle platform, which have seen accelerated project orders and implementations since the Chinese New Year, with over 20 projects currently in progress [3][4]. - The AI middle platform integrates multiple open-source models and has already been implemented in several hospitals, demonstrating its practical application in real-world settings [3][10]. Market Position and Competition - Yidu Technology is positioned as a key player in the AI healthcare market, with a belief that the market is still in its early stages and not yet saturated with competition [8][24]. - The company emphasizes that its competitive edge lies in its extensive data accumulation, algorithmic depth, and application scenarios, which are superior to many competitors in the field [20][33]. Financial Performance and Growth - The company anticipates a 10% annual growth in paid services, with a current coverage of 2,800 hospitals, including 105 top-tier hospitals and over 40 regulatory government clients [4][29]. - There is an expectation of improved financial performance and profitability sooner than previously guided, with a focus on enhancing the gross margin through product mix adjustments [29][30]. Collaboration and Partnerships - Yidu Technology has established a deep partnership with Huawei, leveraging their chip technology and exploring further collaboration opportunities in the healthcare sector [6][7]. - The company is also exploring partnerships with various hospitals and government projects, indicating a robust pipeline of collaborative opportunities [9][16]. Challenges and Future Outlook - The company acknowledges challenges in expanding into lower-tier hospitals due to budget constraints but sees potential for future growth as technology costs decrease and demand for intelligent healthcare solutions increases [41][43]. - There is a strong belief that the AI healthcare market will continue to grow, driven by policy support and increasing hospital budgets for technology investments [16][17]. Miscellaneous Insights - The company has noted a significant increase in project budgets from hospitals and government clients, with some budgets rising from millions to tens of millions [16][17]. - Yidu Technology's AI capabilities are designed to assist in various clinical scenarios, including complex cases, showcasing the versatility and depth of its technology [12][36]. Conclusion Yidu Technology is positioned as a leader in the AI healthcare sector, with a strong foundation of data, innovative products, and strategic partnerships. The company is optimistic about future growth, driven by increasing demand for intelligent healthcare solutions and supportive policies.

基于公司核心算法引擎YiduCore，加之DeepSeek的"出圈"带动医疗行业加速拥抱大模型，医渡科技推出 的AI中台（软硬一体、训推结合）已在20余家三甲医院部署，支持私有化部署及低代码开发，内置分 诊导诊、病历质控等场景化应用。国金证券认为，该产品标准化程度高，有望对公司毛利率带来正向影 响。 医渡科技凭借与105家顶级医院的深度合作及80余个疾病专病库积累，对疾病的理解与认知十分深厚。 并且得益于多场景数据积累及较早进行AI布局，公司大模型能力行业领先，在MedBench、国家卫健委 分导诊能力评测等多项垂类大模型标准化测评中排名第一。 数据+技术双轮驱动，AI中台加速落地 医渡科技深耕AI医疗领域十年，累计经授权处理超55亿份医疗记录，形成基本覆盖全疾病领域的知识 图谱。公司将过往服务中积累的数据处理经验、临床知识图谱、模型训练方法等沉淀形成技术底座 YiduCore，并在此基础上进行大模型训练和AI产品开发。 在大模型生态合作方面，目前公司已经将DeepSeek整合至YiduCore，为研究、诊疗及公共健康等场景提 供更高效低成本的智能化支持。此外，公司还联合华为昇腾AI打造了大模型训推一体解决方 ...

Investment Rating - The report suggests a focus on leading domestic generative model companies such as iFlytek, AI hardware companies like Yingshi Network and Hongsoft Technology, and AI-related applications that can enhance user engagement and payment rates, recommending companies like Kingsoft Office and Wanjing Technology [2] Core Insights - The AI industry chain is expected to maintain high prosperity, with computing power remaining stable and application growth accelerating. Other sectors like intelligent driving and financial IT are also projected to show steady growth [11][12] - The report highlights the recent advancements in AI products, including the launch of free intelligent products by Zhiyuan and significant funding for OpenAI, which will enhance AI research and infrastructure [4][13] - The impact of the recent tariff policy announced by Trump is expected to have a limited effect on the overall performance of the computing sector, as overseas revenue accounts for only about 10% of demand [11] Summary by Sections 1. Industry Perspective - The report discusses the launch of Zhiyuan's free intelligent product "AutoGLM" and the advancements in AI capabilities by Baidu and OpenAI, emphasizing the competitive landscape and technological advancements in the AI sector [11][13] - It notes that the computing sector's performance is likely to be influenced by domestic demand policies and the ongoing trend of domestic substitution and self-control in technology [11] 2. Subsector Insights - AI Industry Chain: High prosperity maintained, with computing power stable and application growth accelerating [10] - Intelligent Driving: Growth is expected to accelerate, particularly in areas like LiDAR and vehicle-road cloud integration [10] - Financial IT: The sector is experiencing steady growth, supported by high trading volumes and favorable policies [14] - Industrial Software: Anticipated breakthroughs in industrial AI applications, with significant projects underway [15] 3. Market Performance - The computing industry index saw a decline of 1.87% from March 31 to April 4, 2025, underperforming compared to the CSI 300 index [16] - The report identifies the top-performing companies in the computing sector during this period, highlighting both gains and losses among key players [22] 4. Upcoming Events - The report outlines several upcoming industry events, including technology exchange days and conferences focused on 6G, drones, and machine learning, suggesting potential investment opportunities in related sectors [29]

Group 1 - The "Belt and Road" initiative has achieved significant results in various fields, particularly in health cooperation, emphasizing the role of digital technology in enhancing healthcare governance along the initiative's routes [1] - The 2025 World Digital Health Forum focused on how digital technology can improve healthcare systems in countries along the "Belt and Road" [1] - Xinjiang Medical University has been actively involved in cross-border medical services, leveraging its geographical advantages to share medical resources and promote telemedicine in Central and South Asia [3][4] Group 2 - The integration of digital technology is seen as a key factor in creating a new corridor for cross-border medical innovation, providing technical, talent, and financial support for healthcare development [4] - Experts suggest localizing computing capabilities to enhance data processing speed and ensure efficient medical services, drawing on China's experience in remote healthcare [6] - Medical technology companies like Yidu Tech are focusing on data governance and standardization to ensure the scientific and international quality of disease data [6][7] Group 3 - Alipay is exploring digital health solutions, enhancing user experiences in medical services through innovations like the medical insurance code, which has over 750 million online users [7] - Alipay's digital health channel connects to 95% of tertiary hospitals in China, creating a one-stop service system that includes various medical services [7] - The company plans to expand its successful models to countries along the "Belt and Road," having already established a presence in 35 countries [7] Group 4 - The globalization of precision medicine requires unified technical standards and ethical consensus, with universities playing a crucial role in talent development [8] - The shift from single technology output to collaborative research models is evident, with companies like Yidu Tech establishing local laboratories to address specific regional needs [8] - Future collaborations will focus on enhancing technical research capabilities and providing tailored digital health solutions for countries along the "Belt and Road" [8][9]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1]. Core Insights - The global new drug business development (BD) remains robust, with approximately 31% of innovative drug candidates introduced by multinational pharmaceutical companies in 2024 coming from China. In the first two months of 2025, there have already been 16 Chinese innovative drug BD projects, expanding from oncology to autoimmune diseases [3]. - The weight loss market is seeing multiple BD agreements, with significant sales figures reported by Novo Nordisk and Eli Lilly. Novo Nordisk's core products generated sales of approximately $27.94 billion in 2024, while Eli Lilly's Mounjaro saw a 124% year-on-year increase in sales to $11.54 billion [5]. - CAR-T cell therapy continues to progress, with global sales expected to reach approximately $4.53 billion in 2024. Chinese companies are also participating in the global CAR-T sales, indicating their technological capabilities [6]. - The gene sequencing industry is accelerating its domestic production capabilities following export restrictions on Illumina's sequencing instruments. Domestic alternatives are rapidly emerging, with several companies receiving regulatory approvals for their sequencing devices [7]. - AI in healthcare is advancing, with various AI models being developed for specific medical fields. Collaborations between tech companies and healthcare providers are enhancing the integration of AI into traditional medical practices [9]. Summary by Sections Industry Trends - The pharmaceutical industry outperformed the CSI 300 index by 0.18 percentage points in the past week, with a weekly increase of 1.77% [23]. - Over the past month, the pharmaceutical sector also outperformed the CSI 300 index by 0.22 percentage points, with a monthly increase of 1.94% [27]. Subsector Performance - The pharmaceutical commercial sector saw the highest weekly increase of 6.44%, while the medical device sector had the lowest at 1.09% [30]. - Over the past year, the chemical pharmaceutical sector had the highest increase of 6.49%, while the biological products sector experienced a decline of 17.62% [37]. Company Recommendations - The report recommends focusing on companies involved in weight loss and NASH, such as Zhongsheng Pharmaceutical, and highlights the potential of companies like Geli Pharmaceutical and Lianbang Pharmaceutical [12]. - Companies engaged in CAR-T technology, such as Kexin Pharmaceutical, are also recommended as they approach market entry [12]. - The report emphasizes the importance of AI integration in medical devices, recommending companies like Anbiping and RunDa Medical for their competitive advantages [12]. Recent Developments - The report notes significant recent financing and regulatory approvals for various companies, indicating a dynamic and evolving market landscape [54][55].

Investment Rating - The report maintains a "Positive" investment rating for the AI+Healthcare industry [6] Core Insights - The reasoning and multimodal capabilities of large models are continuously upgrading, and application costs are decreasing, driving healthcare institutions to accelerate the integration of AI technology. The global generative AI market in healthcare is expected to reach $17.2 billion by 2031, with a compound annual growth rate (CAGR) of 32.60% from 2023 to 2031 [1][18] - The current phase of AI in healthcare has transitioned into a multimodal integration stage, addressing issues such as information silos and data fragmentation that existed in earlier AI applications. Large models utilize a "pre-training + fine-tuning" architecture to process multimodal healthcare data [1][12] - DeepSeek, a domestic open-source large model, is characterized by low cost and high performance, accelerating its penetration into the healthcare industry. It can quickly analyze various types of medical data, aiding doctors in complex case management [2][13] - Major international players like NVIDIA and Microsoft are actively entering the healthcare sector, leveraging their core capabilities through acquisitions and ecosystem empowerment. Companies like Tempus AI and HIMS have successfully commercialized AI solutions, showing significant revenue growth [3][42] Summary by Sections 1. Large Model Technology Upgrade Driving AI in Healthcare - The evolution of AI technology in healthcare has progressed through four key stages: rule-driven systems, traditional machine learning, deep learning with single-modal models, and the current multimodal integration era [11] - The multimodal capabilities of large models enable comprehensive data processing, enhancing clinical decision support, drug development, and telemedicine applications [12][18] 2. International Landscape: Major Players and Innovations - NVIDIA and Microsoft are leading the charge in AI healthcare, with NVIDIA focusing on hardware and ecosystem investments, while Microsoft integrates AI tools into its cloud services [22][28] - Tempus AI has built the largest multimodal database, supporting personalized treatment plans and achieving significant revenue growth [35][37] - HIMS has seen rapid growth in subscription users and revenue, driven by its AI-powered healthcare solutions [42][43] 3. Domestic AI+Healthcare Company Overview - Domestic companies in the AI healthcare sector can be categorized into three types: general large model providers, data service companies, and traditional medical IT companies transitioning to AI [4][47] - iFlytek's Starfire medical model has shown superior performance in diagnostic recommendations and health consultations compared to other models [48][50] - Yunzhisheng is leveraging its self-developed "Shanhai" large model to provide specialized medical information support [54]

2025年3月28日， 清华大学将与中国工程院联合主办 "2025世界数字健康论坛" ，论坛将聚焦 "数智创新·激发健康医疗新格局" 主题，探讨如何借助数字化智能化技 术释放医疗卫生潜力，培养数智健康跨界人才，培育壮大新业态新模式，加速数字健康产业化进程，提升健康治理水平，为构建健康医疗领域新质生产力体系、推 动经济社会高质量发展提供新动能。 思宇MedTech作为"2025世界数字健康论坛"宣传单位 ，诚挚邀请各行业领军企业、创新型企业及有关机构参与本次论坛，共同探讨交流健康医疗行业数字化、智能 化转型未来方向，助力健康中国建设和全球健康事业发展。对贵公司的支持表示由衷的感谢！ 后附2024年会议总结，供感兴趣的企业参考。 一、会议时间： 2025年3月28日星期五 8:30-18:00 权威机构主办： 清华大学、中国工程院；在国家级会议"中关村论坛"上举行。 重量级嘉宾： （部分去年参会嘉宾；排名不分先后）（今年更是盛况空前） 王 辰 中国工程院副院长，中国工程院院士 董家鸿（清华大学临床医学院院长，中国工程院院士） 张伯礼（中国工程院医药卫生学部主任、中国工程院院士、国医大师） 尤 政 华中科技大学校长 ...

出品 | 虎嗅科技医疗组 作者 | 陈广晶 编辑 | 苗正卿 头图 | 视觉中国 同时，接入DeepSeek的AI医疗公司，也在为各大医院量身提供融合了多种模型的AI中台搭建等服务。在监管层面，较为激进的城市已有卫 健委、医保局接入了这一大模型。 "我们业务繁忙，目前各地出差中，忙到要吐了。"有医疗AI公司创业者告诉虎嗅。 相比以往的AI大模型，DeepSeek给相对传统、严谨、保守的医疗行业带来了不小的震撼。 就在前不久，有医生在社交平台爆料，在看诊的过程中，患者用DeepSeek质疑他的诊断结果，这名医生本来很生气，结果回去一查，指南 更新了，是他的诊断过时了。这让他感觉"天塌了"，也让很多基层医生感到天塌了。 而从DeepSeek在医疗领域的更多表现看，这还只是开了一个头。 DeepSeek来势凶猛 人工智能在医疗界也感受到了空前的热情。 "我们必须拥抱AI了。" 在近期多个发布医疗AI大模型的活动现场，都有临床专家这样说。 在经过从豆包到Kimi再到DeepSeek的快速迭代后，即便是中国最顶级的医学专家也感到了"不知所措"。中国工程院院士，上海交通大学医 学院附属瑞金医院院长宁光就曾公开表示，整个社 ...

2025年3月28日， 清华大学将与中国工程院联合主办 "2025世界数字健康论坛" ，论坛将聚焦 "数智创新·激发健康医疗新格局" 主题，探讨如何借助数字化智能化技 术释放医疗卫生潜力，培养数智健康跨界人才，培育壮大新业态新模式，加速数字健康产业化进程，提升健康治理水平，为构建健康医疗领域新质生产力体系、推 动经济社会高质量发展提供新动能。 思宇MedTech作为"2025世界数字健康论坛"宣传单位 ，诚挚邀请各行业领军企业、创新型企业及有关机构参与本次论坛，共同探讨交流健康医疗行业数字化、智能 化转型未来方向，助力健康中国建设和全球健康事业发展。对贵公司的支持表示由衷的感谢！ 后附2024年会议总结，供感兴趣的企业参考。 一、会议时间： 2025年3月28日星期五 8:30-18:00 权威机构主办： 清华大学、中国工程院；在国家级会议"中关村论坛"上举行。 重量级嘉宾： （部分去年参会嘉宾；排名不分先后）（今年更是盛况空前） 王 辰 中国工程院副院长，中国工程院院士 董家鸿（清华大学临床医学院院长，中国工程院院士） 张伯礼（中国工程院医药卫生学部主任、中国工程院院士、国医大师） 尤 政 华中科技大学校长 ...